{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T06:35:10Z","timestamp":1794724510269,"version":"4.9.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T00:00:00Z","timestamp":1721692800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T00:00:00Z","timestamp":1721692800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Three classes of BCMA-directed therapy (BDT) exist: antibody drug-conjugates (ADCs), CAR-T, and T-cell engagers (TCEs), each with distinct strengths and weaknesses. To aid clinicians in selecting between BDTs, we reviewed myeloma patients treated at Mayo Clinic with commercial or investigational BDT between 2018-2023. We identified 339 individuals (1-exposure\u2009=\u2009297, 2-exposures\u2009=\u200938, 3-exposures\u2009=\u20094) who received 385 BDTs (ADC\u2009=\u200959, TCE\u2009=\u2009134, CAR-T\u2009=\u2009192), with median follow-up of 21-months. ADC recipients were older, with more lines of therapy (LOT), and penta-refractory disease. Compared to ADCs, CAR-T (aHR\u2009=\u20090.29, 95%CI\u2009=\u20090.20\u20130.43) and TCEs (aHR\u2009=\u20090.62, 95%CI\u2009=\u20090.43\u20130.91) had better progression-free survival (PFS) on analysis adjusted for age, the presence of extramedullary (EMD), penta-refractory disease, multi-hit high-risk cytogenetics, prior BDT, and the number of LOT in the preceding 1-year. Likewise, compared to ADCs, CAR-T (aHR\u2009=\u20090.28, 95%CI\u2009=\u20090.18\u20130.44) and TCEs (aHR\u2009=\u20090.60, 95%CI\u2009=\u20090.39\u20130.93) had superior overall survival. Prior BDT exposure negatively impacted all classes but was most striking in CAR-T, ORR 86% vs. 50% and median PFS 13-months vs. 3-months. Of relapses, 54% were extramedullary in nature, and a quarter of these cases had no history of EMD. CAR-T demonstrates superior efficacy and where feasible, should be the initial BDT. However, for patients with prior BDT or rapidly progressive disease, an alternative approach may be preferable.<\/jats:p>","DOI":"10.1038\/s41408-024-01081-z","type":"journal-article","created":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T03:02:01Z","timestamp":1721703721000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Clinical features associated with poor response and early relapse following BCMA-directed therapies in multiple myeloma"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8360-2952","authenticated-orcid":false,"given":"Matthew J.","family":"Rees","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aytaj","family":"Mammadzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5812-1954","authenticated-orcid":false,"given":"Abiola","family":"Bolarinwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed E.","family":"Elhaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arwa","family":"Bohra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0964-098X","authenticated-orcid":false,"given":"Radhika","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8377-8111","authenticated-orcid":false,"given":"Sikander","family":"Ailawadhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9314-9933","authenticated-orcid":false,"given":"Ricardo","family":"Parrondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9117-8696","authenticated-orcid":false,"given":"Saurabh","family":"Chhabra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Khot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Hayman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8780-9512","authenticated-orcid":false,"given":"Angela","family":"Dispenzieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3214-0203","authenticated-orcid":false,"given":"Francis","family":"Buadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7477-3004","authenticated-orcid":false,"given":"David","family":"Dingli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahma","family":"Warsame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4342-364X","authenticated-orcid":false,"given":"Prashant","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3853-5196","authenticated-orcid":false,"given":"Morie A.","family":"Gertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2210-2174","authenticated-orcid":false,"given":"Eli","family":"Muchtar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8573-9434","authenticated-orcid":false,"given":"Taxiarchis","family":"Kourelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilson","family":"Gonsalves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5862-1833","authenticated-orcid":false,"given":"S. Vincent","family":"Rajkumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1556-6416","authenticated-orcid":false,"given":"Yi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5392-9284","authenticated-orcid":false,"given":"Shaji","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,23]]},"reference":[{"key":"1081_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-0337-y","volume":"10","author":"A Dogan","year":"2020","unstructured":"Dogan A, Siegel D, Tran N, Fu A, Fowler J, Belani R, et al. B-cell maturation antigen expression across hematologic cancers: a systematic literature review. Blood Cancer J. 2020;10:73.","journal-title":"Blood Cancer J."},{"key":"1081_CR2","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1084\/jem.20031330","volume":"199","author":"BP O\u2019Connor","year":"2004","unstructured":"O\u2019Connor BP, Raman VS, Erickson LD, Cook WJ, Weaver LK, Ahonen C, et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med. 2004;199:91\u20138.","journal-title":"J Exp Med."},{"key":"1081_CR3","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1080\/10428194.2023.2284088","volume":"65","author":"MJ Rees","year":"2024","unstructured":"Rees MJ, Kumar S. BCMA-directed therapy, new treatments in the myeloma toolbox, and how to use them. Leuk Lymphoma. 2024;65:287\u2013300.","journal-title":"Leuk Lymphoma."},{"key":"1081_CR4","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1182\/blood.2022015526","volume":"141","author":"AD Cohen","year":"2023","unstructured":"Cohen AD, Mateos MV, Cohen YC, Rodriguez-Otero P, Paiva B, van de Donk N, et al. Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents. Blood. 2023;141:219\u201330.","journal-title":"Blood."},{"key":"1081_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00886-8","volume":"13","author":"CJ Ferreri","year":"2023","unstructured":"Ferreri CJ, Hildebrandt MAT, Hashmi H, Shune LO, McGuirk JP, Sborov DW, et al. Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy. Blood Cancer J. 2023;13:117.","journal-title":"Blood Cancer J."},{"key":"1081_CR6","doi-asserted-by":"publisher","first-page":"8013","DOI":"10.1200\/JCO.2022.40.16_suppl.8013","volume":"40","author":"C Touzeau","year":"2022","unstructured":"Touzeau C, Krishnan AY, Moreau P, Perrot A, Usmani SZ, Manier S, et al. Efficacy and safety of teclistamab (tec), a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients (pts) with relapsed\/refractory multiple myeloma (RRMM) after exposure to other BCMA-targeted agents. J Clin Oncol. 2022;40:8013.","journal-title":"J Clin Oncol."},{"key":"1081_CR7","doi-asserted-by":"publisher","first-page":"8008","DOI":"10.1200\/JCO.2023.41.16_suppl.8008","volume":"41","author":"AM Lesokhin","year":"2023","unstructured":"Lesokhin AM, Mohty M, Niesvizky R, Maisel C, Arnulf B, Larson SM, et al. Efficacy and safety of elranatamab in patients with relapsed\/refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: a pooled analysis from MagnetisMM studies. J Clin Oncol. 2023;41:8008.","journal-title":"J Clin Oncol."},{"key":"1081_CR8","doi-asserted-by":"publisher","first-page":"e575","DOI":"10.1097\/HS9.0000000000000575","volume":"5","author":"S Ahn","year":"2021","unstructured":"Ahn S, Leblay N, Neri P. Understanding the mechanisms of resistance to T cell-based immunotherapies to develop more favorable strategies in multiple myeloma. Hemasphere. 2021;5:e575\u2013e.","journal-title":"Hemasphere."},{"key":"1081_CR9","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","volume":"29","author":"H Lee","year":"2023","unstructured":"Lee H, Ahn S, Maity R, Leblay N, Ziccheddu B, Truger M, et al. Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma. Nat Med. 2023;29:2295\u2013306.","journal-title":"Nat Med."},{"key":"1081_CR10","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1080\/17474086.2022.2084068","volume":"15","author":"E Watson","year":"2022","unstructured":"Watson E, Djebbari F, Rampotas A, Ramasamy K. BCMA-targeted therapies for multiple myeloma: strategies to maximize efficacy and minimize adverse events. Expert Rev Hematol. 2022;15:503\u201317.","journal-title":"Expert Rev Hematol."},{"key":"1081_CR11","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1056\/NEJMc1206740","volume":"367","author":"D Larson","year":"2012","unstructured":"Larson D, Kyle RA, Rajkumar SV. Prevalence and monitoring of oligosecretory myeloma. N. Engl J Med. 2012;367:580\u20131.","journal-title":"N. Engl J Med."},{"key":"1081_CR12","first-page":"930","volume":"27","author":"MA Dimopoulos","year":"2013","unstructured":"Dimopoulos MA, Kastritis E, Terpos E. Non-secretory myeloma: one, two, or more entities? Oncology. 2013;27:930\u20132.","journal-title":"Oncology."},{"key":"1081_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00587-0","volume":"11","author":"C Fern\u00e1ndez de Larrea","year":"2021","unstructured":"Fern\u00e1ndez de Larrea C, Kyle R, Rosi\u00f1ol L, Paiva B, Engelhardt M, Usmani S, et al. Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage. Blood Cancer J. 2021;11:192.","journal-title":"Blood Cancer J."},{"key":"1081_CR14","doi-asserted-by":"publisher","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","volume":"117","author":"SV Rajkumar","year":"2011","unstructured":"Rajkumar SV, Harousseau J-L, Durie B, Anderson KC, Dimopoulos M, Kyle R, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011;117:4691\u20135.","journal-title":"Blood."},{"key":"1081_CR15","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau P, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, et al. Teclistamab in relapsed or refractory multiple myeloma. N. Engl J Med. 2022;387:495\u2013505.","journal-title":"N. Engl J Med."},{"key":"1081_CR16","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa2303379","volume":"389","author":"J San-Miguel","year":"2023","unstructured":"San-Miguel J, Dhakal B, Yong K, Spencer A, Anguille S, Mateos M-V, et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N. Engl J Med. 2023;389:335\u201347.","journal-title":"N. Engl J Med."},{"key":"1081_CR17","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","volume":"388","author":"P Rodriguez-Otero","year":"2023","unstructured":"Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N. Engl J Med. 2023;388:1002\u201314.","journal-title":"N. Engl J Med."},{"key":"1081_CR18","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","volume":"21","author":"S Lonial","year":"2020","unstructured":"Lonial S, Lee HC, Badros A, Trudel S, Nooka AK, Chari A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020;21:207\u201321.","journal-title":"Lancet Oncol."},{"key":"1081_CR19","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1038\/s41591-023-02589-w","volume":"29","author":"NJ Bahlis","year":"2023","unstructured":"Bahlis NJ, Costello CL, Raje NS, Levy MY, Dholaria B, Solh M, et al. Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial. Nat Med. 2023;29:2570\u20136.","journal-title":"Nat Med."},{"key":"1081_CR20","doi-asserted-by":"publisher","first-page":"8009","DOI":"10.1200\/JCO.2023.41.16_suppl.8009","volume":"41","author":"Y Lin","year":"2023","unstructured":"Lin Y, Martin TG, Usmani SZ, Berdeja JG, Jakubowiak AJ, Agha ME, et al. CARTITUDE-1 final results: Phase 1b\/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed\/refractory multiple myeloma. J Clin Oncol. 2023;41:8009.","journal-title":"J Clin Oncol."},{"key":"1081_CR21","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1182\/blood.2022017848","volume":"141","author":"O Van Oekelen","year":"2023","unstructured":"Van Oekelen O, Nath K, Mouhieddine TH, Farzana T, Aleman A, Melnekoff DT, et al. Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy. Blood. 2023;141:756\u201365.","journal-title":"Blood."},{"key":"1081_CR22","doi-asserted-by":"publisher","first-page":"S34","DOI":"10.1016\/j.jtct.2023.12.051","volume":"30","author":"M Janakiram","year":"2024","unstructured":"Janakiram M, Khouri J, Castaneda O, Shune L, Dima D, Kaur G, et al. Immune Engager Therapies Are Associated with Better Outcomes in Post Ide-Cel Relapse in MM- an Analysis of the US MM Immunotherapy Consortium Database. Transplant Cell Ther. 2024;30:S34\u2013S5.","journal-title":"Transplant Cell Ther."},{"key":"1081_CR23","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.ccell.2023.02.008","volume":"41","author":"MJ Friedrich","year":"2023","unstructured":"Friedrich MJ, Neri P, Kehl N, Michel J, Steiger S, Kilian M, et al. The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients. Cancer Cell. 2023;41:711\u201325.e6.","journal-title":"Cancer Cell."},{"key":"1081_CR24","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1182\/blood.2022015956","volume":"140","author":"N Philipp","year":"2022","unstructured":"Philipp N, Kazerani M, Nicholls A, Vick B, Wulf J, Straub T, et al. T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals. Blood. 2022;140:1104\u201318.","journal-title":"Blood."},{"key":"1081_CR25","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1182\/blood-2023-187242","volume":"142","author":"AJ Jakubowiak","year":"2023","unstructured":"Jakubowiak AJ, Anguille S, Karlin L, Chari A, Schinke C, Rasche L, et al. Updated results of Talquetamab, a GPRC5D\u00d7CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma with prior exposure to T-cell redirecting therapies: results of the phase 1\/2 monumenTAL-1 study. Blood. 2023;142:3377.","journal-title":"Blood."},{"key":"1081_CR26","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1182\/blood-2023-180421","volume":"142","author":"D Dima","year":"2023","unstructured":"Dima D, Davis JA, Ahmed N, Sannareddy A, Shaikh H, Mahmoudjafari Z, et al. Real-world safety and efficacy of Teclistamab for patients with heavily pretreated relapsed-refractory multiple myeloma. Blood. 2023;142:91.","journal-title":"Blood."},{"key":"1081_CR27","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1158\/1535-7163.MCT-21-0035","volume":"20","author":"R Montes de Oca","year":"2021","unstructured":"Montes de Oca R, Alavi AS, Vitali N, Bhattacharya S, Blackwell C, Patel K, et al. Belantamab mafodotin (GSK2857916) drives immunogenic cell death and immune-mediated antitumor responses in vivo. Mol Cancer Ther. 2021;20:1941\u201355.","journal-title":"Mol Cancer Ther."},{"key":"1081_CR28","doi-asserted-by":"publisher","first-page":"8021","DOI":"10.1200\/JCO.2022.40.16_suppl.8021","volume":"40","author":"J Rytlewski","year":"2022","unstructured":"Rytlewski J, Fuller J, Mertz DR, Freeman C, Manier S, Shah N, et al. Correlative analysis to define patient profiles associated with manufacturing and clinical endpoints in relapsed\/refractory multiple myeloma (RRMM) patients treated with idecabtagene vicleucel (ide-cel; bb2121), an anti-BCMA CAR T cell therapy. J Clin Oncol. 2022;40:8021.","journal-title":"J Clin Oncol."},{"key":"1081_CR29","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1182\/blood-2022-162709","volume":"140","author":"D Cortes-Selva","year":"2022","unstructured":"Cortes-Selva D, Casneuf T, Vishwamitra D, Stein S, Perova T, Skerget S, et al. Teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM): correlative analyses from MajesTEC-1. Blood. 2022;140:241\u20133.","journal-title":"Blood."},{"key":"1081_CR30","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1002\/ajh.27023","volume":"98","author":"S Zanwar","year":"2023","unstructured":"Zanwar S, Ho M, Lin Y, Kapoor P, Binder M, Buadi FK, et al. Natural history, predictors of development of extramedullary disease, and treatment outcomes for patients with extramedullary multiple myeloma. Am J Hematol. 2023;98:1540\u20139.","journal-title":"Am J Hematol."},{"key":"1081_CR31","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s00277-016-2847-z","volume":"96","author":"S Mangiacavalli","year":"2017","unstructured":"Mangiacavalli S, Pompa A, Ferretti V, Klersy C, Cocito F, Varettoni M, et al. The possible role of burden of therapy on the risk of myeloma extramedullary spread. Ann Hematol. 2017;96:73\u201380.","journal-title":"Ann Hematol."},{"key":"1081_CR32","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","volume":"380","author":"N Raje","year":"2019","unstructured":"Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N. Engl J Med. 2019;380:1726\u201337.","journal-title":"N. Engl J Med."},{"key":"1081_CR33","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1182\/blood-2020-139063","volume":"136","author":"M Wang","year":"2020","unstructured":"Wang M, Munoz J, Goy AH, Locke FL, Jacobson CA, Hill BT, et al. One-year follow-up of ZUMA-2, the multicenter, registrational study of KTE-X19 in patients with relapsed\/refractory mantle cell lymphoma. Blood.2020;136:20\u20132.","journal-title":"Blood."},{"key":"1081_CR34","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1182\/blood-2023-190019","volume":"142","author":"CTR Vegivinti","year":"2023","unstructured":"Vegivinti CTR, Lawrence Alexander Santhi J, Liu L, Keesari PR, Thakur R, Hammami MB, et al. Efficacy of bispecific antibodies Vs CAR-T in the treatment of extramedullary disease and high-risk cytogenetics in relapsed multiple myeloma: a systematic review and meta-analysis. Blood. 2023;142:1994.","journal-title":"Blood."},{"key":"1081_CR35","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1200\/JCO.22.00842","volume":"41","author":"T Martin","year":"2023","unstructured":"Martin T, Usmani SZ, Berdeja JG, Agha M, Cohen AD, Hari P, et al. Ciltacabtagene autoleucel, an anti\u2013B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol. 2023;41:1265\u201374.","journal-title":"J Clin Oncol."},{"key":"1081_CR36","doi-asserted-by":"publisher","first-page":"4688","DOI":"10.1182\/blood-2023-188080","volume":"142","author":"H Lee","year":"2023","unstructured":"Lee H, Durante M, Ahn S, Leblay N, Poorebrahim M, Maity R, et al. The impact of soluble BCMA and BCMA gain on anti-BCMA immunotherapies in multiple myeloma. Blood.2023;142:4688.","journal-title":"Blood."},{"key":"1081_CR37","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.leukres.2019.04.008","volume":"81","author":"H Chen","year":"2019","unstructured":"Chen H, Li M, Xu N, Ng N, Sanchez E, Soof CM, et al. Serum B-cell maturation antigen (BCMA) reduces binding of anti-BCMA antibody to multiple myeloma cells. Leuk Res. 2019;81:62\u20136.","journal-title":"Leuk Res."},{"key":"1081_CR38","doi-asserted-by":"publisher","first-page":"8006","DOI":"10.1200\/JCO.2023.41.16_suppl.8006","volume":"41","author":"HC Lee","year":"2023","unstructured":"Lee HC, Bumma N, Richter JR, Dhodapkar MV, Hoffman JE, Suvannasankha A, et al. LINKER-MM1 study: Linvoseltamab (REGN5458) in patients with relapsed\/refractory multiple myeloma. J Clin Oncol. 2023;41:8006.","journal-title":"J Clin Oncol."},{"key":"1081_CR39","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1182\/blood.2019000050","volume":"134","author":"MJ Pont","year":"2019","unstructured":"Pont MJ, Hill T, Cole GO, Abbott JJ, Kelliher J, Salter AI, et al. \u03b3-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma. Blood. 2019;134:1585\u201397.","journal-title":"Blood."},{"key":"1081_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00716-3","volume":"12","author":"H Chen","year":"2022","unstructured":"Chen H, Yu T, Lin L, Xing L, Cho S-F, Wen K, et al. \u03b3-secretase inhibitors augment efficacy of BCMA-targeting bispecific antibodies against multiple myeloma cells without impairing T-cell activation and differentiation. Blood Cancer J. 2022;12:118.","journal-title":"Blood Cancer J."},{"key":"1081_CR41","doi-asserted-by":"publisher","first-page":"8019","DOI":"10.1200\/JCO.2022.40.16_suppl.8019","volume":"40","author":"S Lonial","year":"2022","unstructured":"Lonial S, Grosicki S, Hus M, Song KW, Facon T, Callander NS, et al. Synergistic effects of low-dose belantamab mafodotin in combination with a gamma-secretase inhibitor (nirogacestat) in patients with relapsed\/refractory multiple myeloma (RRMM): DREAMM-5 study. J Clin Oncol. 2022;40:8019.","journal-title":"J Clin Oncol."},{"key":"1081_CR42","doi-asserted-by":"publisher","first-page":"e1257964","DOI":"10.1097\/01.HS9.0000967688.12579.64","volume":"7","author":"F Offner","year":"2023","unstructured":"Offner F, Decaux O, Hulin C, Anguille S, Sophie Michallet A, Costa L, et al. Teclistamab and nirogacestat in relapsed\/refractory multiple myeloma: the phase 1B MAJESTIC-2 Study. Hemasphere. 2023;7:e1257964.","journal-title":"Hemasphere."},{"key":"1081_CR43","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/S1470-2045(23)00246-2","volume":"24","author":"AJ Cowan","year":"2023","unstructured":"Cowan AJ, Pont MJ, Sather BD, Turtle CJ, Till BG, Libby EN 3rd, et al. \u03b3-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial. Lancet Oncol. 2023;24:811\u201322.","journal-title":"Lancet Oncol."},{"key":"1081_CR44","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","volume":"387","author":"A Chari","year":"2022","unstructured":"Chari A, Minnema MC, Berdeja JG, Oriol A, van de Donk NWCJ, Rodr\u00edguez-Otero P, et al. Talquetamab, a T-cell\u2013redirecting GPRC5D bispecific antibody for multiple myeloma. N. Engl J Med. 2022;387:2232\u201344.","journal-title":"N. Engl J Med."},{"key":"1081_CR45","doi-asserted-by":"publisher","first-page":"8036","DOI":"10.1200\/JCO.2023.41.16_suppl.8036","volume":"41","author":"CD Schinke","year":"2023","unstructured":"Schinke CD, Touzeau C, Minnema MC, van de Donk NWCJ, Rodr\u00edguez-Otero P, Mateos M-V, et al. Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed\/refractory multiple myeloma (RRMM). J Clin Oncol. 2023;41:8036.","journal-title":"J Clin Oncol."},{"key":"1081_CR46","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1182\/blood-2023-185980","volume":"142","author":"A Zabaleta","year":"2023","unstructured":"Zabaleta A, Puig N, Cedena Romero MT, Perez JJ, Moreno C, Tamariz-Amador L-E, et al. Clinical significance of measurable residual disease (MRD) in relapsed\/refractory multiple myeloma (RRMM) patients (Pts) treated with chimeric antigen receptor (CAR) T cells and T-cell engagers (TCE). Blood. 2023;142:94.","journal-title":"Blood."},{"key":"1081_CR47","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.3324\/haematol.2017.177139","volume":"103","author":"FE Davies","year":"2018","unstructured":"Davies FE, Rosenthal A, Rasche L, Petty NM, McDonald JE, Ntambi JA, et al. Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myeloma. Haematologica. 2018;103:1047\u201353.","journal-title":"Haematologica."},{"key":"1081_CR48","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1200\/JCO.2017.72.2975","volume":"35","author":"P Moreau","year":"2017","unstructured":"Moreau P, Attal M, Caillot D, Macro M, Karlin L, Garderet L, et al. Prospective evaluation of magnetic resonance imaging and [(18)F]fluorodeoxyglucose positron emission tomography-computed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM\/DFCI 2009 trial: results of the IMAJEM study. J Clin Oncol. 2017;35:2911\u20138.","journal-title":"J Clin Oncol."}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01081-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01081-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01081-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T16:21:31Z","timestamp":1721751691000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01081-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,23]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1081"],"URL":"https:\/\/doi.org\/10.1038\/s41408-024-01081-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4254335\/v1","asserted-by":"object"}]},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,23]]},"assertion":[{"value":"11 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SVR reports grants from NIH, outside the submitted work. PK received research funding from Takeda Pharmaceuticals, Celgene, Sanofi, AbbVie, Karyopharm Therapeutics, Sorrento Therapeutics, Ichnos Sciences, and Amgen. AD received research funding from Celgene, Millennium Pharmaceuticals, Pfizer, Prothena, and Janssen and received a travel grant from Pfizer. MAG served as a consultant for Millennium Pharmaceuticals and received honoraria from Celgene, Millennium Pharmaceuticals, Onyx Pharmaceuticals, Novartis, GlaxoSmithKline, Prothena, Ionis Pharmaceuticals, and Amgen. SA served as a consultant for Takeda, Beigene, GlaxoSmithKline, Bristol-Myers Squib, Amgen, Janssen, Regeneron, and Cellectar and received research funding from Pharmacyclics, Janssen Biotech, Cellectar, Bristol-Myers Squibb, Amgen, AbbVie and Sanofi. SC received research funding from Janssen, CARsgen Therapeutics, C4 Therapeutics, and Abbvie. YL served as a consultant for Kite, Bristol-Myers Squibb, Vineti, Janssen Oncology, Pfizer, Sanofi, NexImmune, Caribou Biosciences, Regeneron, Genentech, Chimeric Therapeutics, Adicet Bio and Nektar and received research funding from Janssen Oncology and Bristol-Myers Squibb. DD has served as a consultant for Bristol-Myers Squibb, Novartis, Genentech, Apellis Pharmaceuticals, AstraZeneca, Sanofi, and Takeda. SK served as a consultant for Celgene, Millennium Pharmaceuticals, Onyx Pharmaceuticals, Janssen, and Bristol-Myers Squibb and received research funding from Celgene, Millennium Pharmaceuticals, Novartis, Onyx Pharmaceuticals, AbbVie, Janssen, and Bristol-Myers Squibb. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Research was conducted in accordance with the declaration of Helsinki. Approval to conduct the study was provided by the Mayo Clinic Institutional Review Board (IRB: 23-007084). Informed consent was obtained from all subjects for use of their medical records.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"122"}}